Coherus BioSciences Management to Present at the 40th Annual J.P. Morgan Healthcare Conference

2 years ago

REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management…

Yield10 Bioscience to Present at the H.C. Wainwright Bioconnect Virtual Conference

2 years ago

WOBURN, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, announced today that…

Conformis, Inc. to Provide Business Update and Initial Expectations for 2022 on January 6, 2022

2 years ago

BILLERICA, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will provide a business…

Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint

2 years ago

‒ Company plans to initiate multi-national Phase 3 Trial in 2022 ‒BOSTON and JERUSALEM, Israel, Jan. 04, 2022 (GLOBE NEWSWIRE) --…

Vericel to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

2 years ago

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine…

Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking Cessation

2 years ago

Topline ORCA-2 Results Expected in Q2 2022SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Achieve Life…

Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs

2 years ago

Receives a Notice of Allowance of Multiple Patent Claims for TNX-102 (subcutaneous levosimendan) Successfully Completes IV to Oral Transition Substudy…

Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2

2 years ago

Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. Clinically important bradycardia is common in heart failure (HF)…

Allogene Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference

2 years ago

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering…

POINT Biopharma Adds Senior BD Expertise with Appointment of Dr. Matthew Vincent as SVP, Business Development

2 years ago

Dr. Vincent brings more than 25 years of pharma business development experience along with deep technical expertise including drug development…